Balancing Innovation with Risk and Regulation to Drive Sustained Performance

The life sciences industry is heavily concentrated in the middle market. It is made up of a diverse ecosystem of businesses that work together to innovate, research, test, develop, produce, and distribute pharmaceuticals, medical devices, and supplements to healthcare providers and their patients. The success of middle market life sciences businesses helps to drive not only the economic well-being of the United States and Canada but also the personal well-being of every individual.

In this report, fielded just prior to the onset of the global COVID-19 pandemic, the National Center for the Middle Market and its partners explored the unique aspects of this crucial industry, including its focus on innovation, complex set of risks and exposures, and multifaceted regulatory environment. We looked at the most pressing challenges faced by the businesses as well as the capabilities needed to overcome hurdles and sustain successful growth. Finally, in follow up interviews, we asked life sciences executive about the impact of COVID-19 and how it might alter the business landscape going forward. The report shares the findings and can serve as a platform for middle market life sciences executives, regulators, and economic development agencies invested in the ongoing vitality of the life sciences sector.


Subscribe to receive our latest research, insights and perspectives
The information you provide will be used in accordance with the terms of our privacy policy.